OraSure Technologies, Inc. (OSUR)
NASDAQ: OSUR · Real-Time Price · USD
3.430
-0.060 (-1.72%)
At close: Mar 28, 2025, 4:00 PM
3.485
+0.055 (1.59%)
After-hours: Mar 28, 2025, 7:50 PM EDT

Company Description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally.

The company’s products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples.

In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community.

Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae.

The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets.

OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

OraSure Technologies, Inc.
OraSure Technologies logo
Country United States
Founded 2000
IPO Date Nov 12, 1986
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 501
CEO Carrie Eglinton Manner

Contact Details

Address:
220 East First Street
Bethlehem, Pennsylvania 18015
United States
Phone 610 882 1820
Website orasure.com

Stock Details

Ticker Symbol OSUR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001116463
CUSIP Number 68554V108
ISIN Number US68554V1089
Employer ID 36-4370966
SIC Code 3841

Key Executives

Name Position
Carrie Eglinton Manner President, Chief Executive Officer and Director
Kenneth J. McGrath Chief Financial Officer
Kathleen Gallagher Weber Chief Product Officer
Michele Anthony Senior Vice President, Chief Accounting Officer, Controller and Assistant Secretary
Rafal Iwasiow Ph.D. Vice President of Science, Innovation and Technology
Jason Michael Plagman Vice President of Investor Relations
Stefano Taucer General Counsel and Corporate Secretary
David A. Rappaport C.F.A. Senior Vice President Corporate Development, Strategy and Integration
Amy Steigerwalt Senior Vice President of Human Resources
Zachary Wert Senior Vice President of Global Operations

Latest SEC Filings

Date Type Title
Mar 24, 2025 8-K Current Report
Mar 7, 2025 10-K Annual Report
Mar 7, 2025 8-K/A [Amend] Current report
Feb 25, 2025 8-K Current Report
Jan 7, 2025 SCHEDULE 13G/A Filing
Dec 26, 2024 8-K Current Report
Dec 19, 2024 8-K Current Report
Dec 4, 2024 UPLOAD Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 10-Q Quarterly Report